Deucravacitinib-13C,d3

Deucravacitinib-13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Formel: C1913CH19D3N8O3
  • Molecular Weight:426.45
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Alle JAK Isoform-spezifische Produkte anzeigen

More

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00